论文部分内容阅读
目的探讨动脉灌注多西他赛和表柔比星治疗乳腺癌术后胸壁复发的疗效及不良反应。方法选取2013年10月至2016年1月间中国石油天然气集团公司中心医院收治的75例乳腺癌术后单纯胸壁复发患者,根据化疗药物给药方式不同分为研究组和对照组。研究组患者28例,通过锁骨下动脉造影,确认复发区供血动脉,行动脉灌注化疗,实际完成25例。对照组患者47例,静脉给药化疗,实际完成40例。比较两组患者化疗效果及不良反应发生率。结果研究组患者化疗总有效率为80.0%,对照组患者为52.5%,差异有统计学意义(P<0.05)。两组患者主要不良反应为骨髓抑制和消化道反应,研究组骨髓抑制发生率为16.7%,对照组为29.2%。研究组患者消化道反应发生率为41.7%,对照组为57.7%,两组比较,差异均有统计学意义(均P<0.05)。结论乳腺癌术后胸壁复发患者经动脉灌注化疗有效率高,不良反应少,安全有效,值得临床推广。
Objective To investigate the efficacy and adverse reactions of arterial infusion of docetaxel and epirubicin in the treatment of postoperative chest wall recurrence of breast cancer. Methods Seventy-five patients with recurrent chest wall cancer after breast cancer surgery were selected from the Central Hospital of China National Petroleum Corporation from October 2013 to January 2016. The patients were divided into study group and control group according to different modes of administration of chemotherapy drugs. The study group of 28 patients, through the subclavian artery angiography to confirm the recurrence of the donor artery, arterial infusion chemotherapy, the actual completion of 25 cases. The control group of 47 patients, intravenous chemotherapy, the actual completion of 40 cases. The effects of chemotherapy and the incidence of adverse reactions in the two groups were compared. Results The total effective rate of chemotherapy was 80.0% in study group and 52.5% in control group, the difference was statistically significant (P <0.05). The main adverse reactions in both groups were myelosuppression and digestive tract response. The incidence of myelosuppression in the study group was 16.7% and in the control group 29.2%. The incidence of gastrointestinal reactions was 41.7% in the study group and 57.7% in the control group. There was significant difference between the two groups (all P <0.05). Conclusion Breast cancer patients with chest wall recurrence after transcatheter arterial infusion chemotherapy with high efficiency, fewer adverse reactions, safe and effective, worthy of clinical promotion.